Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | GPR35 | Q9HC97 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.40 |
| ▸ | GRIN2D | O15399 | 3/20 | 0.39 |
| ▸ | GRIN3B | O60391 | 3/20 | 0.39 |
| ▸ | GRIN1 | Q05586 | 3/20 | 0.39 |
| ▸ | GRIN2A | Q12879 | 3/20 | 0.39 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL610592 | 0.84 | TSHR (0.47) | TSHRPOLBCYP1A2CYP2D6CYP2C9 | |
| SCHEMBL9132988 | 0.81 | TSHR (0.60) | TSHRKMT2AKDM4ETDP1CYP1A2 | |
| SCHEMBL31470133 | 0.79 | SMN1; SMN2 (0.49) | TSHRPOLBKMT2AKDM4ECTDSP1 | |
| SCHEMBL7902778 | 0.79 | SMN1; SMN2 (0.49) | TSHRPOLBKMT2AKDM4ECTDSP1 | |
| SCHEMBL29185997 | 0.77 | ALDH1A1 (0.46) | TSHRTDP1CYP1A2CYP2D6CYP2C9 | |
| SCHEMBL5064995 | 0.76 | TSHR (0.72) | TSHRPOLBKMT2ACYP1A2CYP2D6 | |
| SCHEMBL29186004 | 0.75 | AKR1C2 (0.44) | TSHRKMT2AKDM4ETDP1CYP1A2 | |
| SCHEMBL3239416 | 0.74 | ALDH1A1 (0.48) | TSHRPOLBKMT2ACTDSP1TDP1 | |
| SCHEMBL28030677 | 0.74 | KMT2A (0.61) | TSHRKMT2AGPR35ALDH1A1CYP3A4 | |
| SCHEMBL10495780 | 0.74 | HSD17B10 (0.50) | TSHRPOLBKMT2ACYP1A2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1558585-B1 | NEUROLOGICALLY-ACTIVE COMPOUNDS | PRANA BIOTECHNOLOGY LTD (AU) | 2013-09-25 | — | — | EP | disclosed |
| EP-1558585-B1 | NEUROLOGICALLY-ACTIVE COMPOUNDS | PRANA BIOTECHNOLOGY LTD (AU) | 2013-09-25 | — | — | EP | disclosed |
| US-8084459-B2 | 8-hydroxy-3H-quinazolin-4-(thi)one derivatives; ability to enter CNS, sequester transition metals Cu, Zn and Fe from various amiloid beta entities, reducing their toxicity; neurodegenerative disorders; Alzheimer's, Parkinson's, Cruetzfeldt-Jacob diseases, amyotrophic lateral sclerosis, cataract | PRANA BIOTECHNOLOGY LTD (AU) | 2011-12-27 | — | — | US | disclosed |
| EP-2210892-A2 | Neurologically-active compounds | Prana Biotechnology Limited (AU) | 2010-07-28 | — | — | EP | disclosed |
| US-20100160346-A1 | NEUROLOGICALLY ACTIVE COMPOUNDS | PRANA BIOTECHNOLOGY LIMITED (AU) | 2010-06-24 | — | — | US | disclosed |
| US-20100160346-A1 | NEUROLOGICALLY ACTIVE COMPOUNDS | PRANA BIOTECHNOLOGY LIMITED (AU) | 2010-06-24 | — | — | US | disclosed |
| US-20100160346-A1 | NEUROLOGICALLY ACTIVE COMPOUNDS | PRANA BIOTECHNOLOGY LIMITED (AU) | 2010-06-24 | — | — | US | disclosed |
| US-7692011-B2 | 8-hydroxy and 8-mercapto quinazolinones | PRANA BIOTECHNOLOGY LIMITED (AU) | 2010-04-06 | — | — | US | disclosed |
| US-7692011-B2 | 8-hydroxy and 8-mercapto quinazolinones | PRANA BIOTECHNOLOGY LIMITED (AU) | 2010-04-06 | — | — | US | disclosed |
| US-7692011-B2 | 8-hydroxy and 8-mercapto quinazolinones | PRANA BIOTECHNOLOGY LIMITED (AU) | 2010-04-06 | — | — | US | disclosed |
| EP-1558585-A4 | NEUROLOGICALLY-ACTIVE COMPOUNDS | PRANA BIOTECHNOLOGY LTD (AU) | 2008-07-02 | — | — | EP | disclosed |
| US-20060167000-A1 | Neurologically-active compounds | PRANA BIOTECHNOLOGY LIMITED (AU) | 2006-07-27 | — | — | US | disclosed |
| WO-2005095360-A1 | NEUROLOGICALLY-ACTIVE COMPOUNDS | PRANA BIOTECHNOLOGY LIMITED (AU) | 2005-10-13 | — | — | WO | disclosed |
| EP-1558585-A1 | NEUROLOGICALLY-ACTIVE COMPOUNDS | Prana Biotechnology Ltd (AU) | 2005-08-03 | — | — | EP | disclosed |
| WO-2004031161-A1 | NEUROLOGICALLY-ACTIVE COMPOUNDS | PRANA BIOTECHNOLOGY LIMITED (AU) | 2004-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060167000-A1 | Neurologically-active compounds | ACHE, PSEN1, PSEN2 | TSHR 4668/4885POLB 2647/4885KMT2A 2506/4885 |
| US-20100160346-A1 | NEUROLOGICALLY ACTIVE COMPOUNDS | ACHE, PSEN1, PSEN2 | TSHR 4642/4885POLB 2953/4885KMT2A 2765/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.